Invest in SPDR S&P Biotech ETF (XBI) for long-term growth potential and diverse, equal-weighted portfolio in the biotech ...

"We thank our stockholders for their support through our time as a public company and the duration of this process,” said Nick Green, president and CEO of Avid Bioservices. "We look forward to ...

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...

A new project to address vulnerabilities in the UK’s food supply chain – and protect the country from potential shortages – has been launched thanks to funding from UK Research and Innovation (UKRI).

PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing ...

The freeze, even if it ends up only lasting a few weeks, would hit St. Louis particularly hard. In addition to WashU, St.

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

As CTO, Mr. Beneski will oversee Allogene's technical operations, leveraging his extensive expertise in biologics ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology ...

From a margin perspective, Danaher's operations should eventually improve once top-line growth rebounds. With that operating leverage-related margin expansion, we expect Danaher's adjusted EPS to grow ...

A Loughborough University-backed research project investigating the development of new treatments for drug-resistant ...